Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: A case report

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 52, Issue 4, 2007, Pages 329-331

  Fischer, Gayle ^a   Bradford, Jennifer ^a  

^a NONE

Author keywords

Lichen sclerosus; Pimecrolimus; Tacrolimus; Vulvar diseases

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METHYLPREDNISOLONE ACEPONATE; PIMECROLIMUS; TACROLIMUS;

AGED; ARTICLE; CANCER RISK; CASE REPORT; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LICHEN SCLEROSUS ET ATROPHICUS; PRIORITY JOURNAL; PSORIASIS; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; VULVA; VULVA TUMOR; VULVITIS;

EID: 34247635150     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Dalziel KL, Millard PR, Wojnarowska F: The treatment of vulvar lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991;124:461-464
2. Bracco GL, Carle P, Sonni L, et al: Clinical and histologic effects of topical treatments of vulval lichen sclerosus: A critical evaluation. J Reprod Med 1993;38:37-40
3. Byrd JA, Davis MDP, Rogers R III: Reclacitrant symptomatic vulvar lichen planus: Response to topical tacrolimus. Arch Dermatol 2004;140:715-720
4. Reitamo S, Rissanene J, Remitz A, et al: Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998;111:396-398
5. Bohm M, Frieling U, Luger TA, et al: Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139:922-924
6. Kunsfield R, Kirnbauer R, Stingl G, et al: Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139:850-552
7. Assmann T, Becker-Wegerich P, Grewe M, et al: Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003;48:935-937
8. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004:17:35-37
9. Godstein AT, Marinoff SC, Christopher: Pimecrolimus for the treatment of vulvar lichen sclerosus: A report of 4 cases. J Reprod Med 2004;49:778-780
10. Carlson JA, Ambros R, Malfetano J, et al: Vulvar lichen sclerosus and squamous cell carcinoma: A cohort, case control, and investigational study with historical perspective: Implications for chronic inflammation and sclerosus in the development of neoplasia. Hum Pathol 1998;29:932-948
11. Powell JJ, Wojnarowska F: Lichen sclerosus. Lancet 1999;353:1777-1783
12. Derrick EK, Ridley CM, Kobza-Black A, et al: A clinical study of 23 cases of female genital anogenital carcinoma. Br J Dermatol 2000; 143:1217-1223
13. Bunker CB, Neill S, Staughton RCD: Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. Arch Dermatol 2004;140:1169
14. Cooper SM, Gao X-H, Powell JJ, et al: Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol 2004;140:702-706
15. Scurry J, Whitehead F, Healey M: Histopathology of lichen sclerosus varies according to site and proximity to carcinoma. Am J Dermatopathol 2000;23:413-418
16. Dalziel K, Wojnarowska F: Long-term control of vulvar lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med 1993;38:25-27
17. Renaud-Vilmer C, Calelier-Blloy B, Porcher R, et al: Vulvar lichen sclerosus: Effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2003;140:709-712
18. Niwa Y, Terashima T, Sumi H: Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960-967